Basmisanil

Basmisanil
Clinical data
Other namesRG-1662; RO5186582
ATC code
  • None
Identifiers
  • (1,1-Dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H20FN3O5S
Molar mass445.47 g·mol−1
3D model (JSmol)
  • CC1=C(C(=NO1)C2=CC=C(C=C2)F)COC3=NC=C(C=C3)C(=O)N4CCS(=O)(=O)CC4
  • InChI=1S/C21H20FN3O5S/c1-14-18(20(24-30-14)15-2-5-17(22)6-3-15)13-29-19-7-4-16(12-23-19)21(26)25-8-10-31(27,28)11-9-25/h2-7,12H,8-11,13H2,1H3
  • Key:VCGRFBXVSFAGGA-UHFFFAOYSA-N

Basmisanil (INNTooltip International Nonproprietary Name; developmental codes RG-1662 and RO5186582) is a highly selective inverse agonist/negative allosteric modulator of α5 subunit-containing GABAA receptors which is under development by Roche for the treatment of cognitive impairment associated with Down syndrome.[1][2][3] As of June 2016, it is no longer studied for this purpose.[4] It underwent a clinical trial for cognitive impairment in patients with schizophrenia.[5]

See also

References

  1. ^ Froestl W, Muhs A, Pfeifer A (2012). "Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors". Journal of Alzheimer's Disease. 32 (4): 793–887. doi:10.3233/JAD-2012-121186. PMID 22886028.
  2. ^ Hurley D (2013). "Investigators Silence Trisomy 21 Chromosome in Human Down Syndrome Cells". Neurology Today. 13 (17): 14–15. doi:10.1097/01.NT.0000434604.55014.fd. ISSN 1533-7006.
  3. ^ Jensen HS, Nichol K, Lee D, Ebert B (2014). "Clobazam and its active metabolite N-desmethylclobazam display significantly greater affinities for α₂- versus α₁-GABA(A)-receptor complexes". PLOS ONE. 9 (2): e88456. Bibcode:2014PLoSO...988456J. doi:10.1371/journal.pone.0088456. PMC 3922815. PMID 24533090.
  4. ^ Chevrette M. "Response to the Roche Clinical Trial for CLEMATIS". Retrieved 2016-06-28.
  5. ^ Clinical trial number NCT02953639 for "A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics" at ClinicalTrials.gov
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.